Marina Biotech to Explore Strategic Alternatives BOTHELL,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Marina Biotech to Explore Strategic Alternatives

BOTHELL, WA--(Marketwired - Feb 17, 2016) - Marina Biotech, Inc. ( OTCQB : MRNA ), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that its Board of Directors has authorized a process to explore a range of strategic alternatives to enhance shareholder value. Marina is a biotechnology company focused on the discovery, development and commercialization of nucleic acid−based therapies to treat orphan diseases. Marina's lead clinical program is CEQ508 for the treatment of Familial Adenomatous Polyposis, which has been granted U.S. Food and Drug Administration Orphan Drug and Fast Track designations. In addition, the Company has preclinical programs for the treatment of type 1 myotonic dystrophy and Duchenne muscular dystrophy. The Company has a strong intellectual property portfolio validated through multiple license agreements supporting both novel nucleic acid chemistry platforms as well as one of the most versatile delivery technologies in the nucleic acid therapeutics sector. The Company's SMARTICLES ® technology has been administered to over 130 patients delivering both single- and double-stranded oligonucleotide therapeutics.

"The Board of Directors for Marina has determined that it is in the best interest of its shareholders to consider itself a possible acquisition target to a strategic company that possesses the necessary resources to invest in and capitalize on the significant potential of Marina's proprietary delivery technologies, novel chemistries and rare disease pipeline," stated Joseph W. Ramelli, chair of the independent Special Committee of the Board. "The Board of Directors believe that this may be the most advantageous path to advance the Company's IP and assets, and has appointed an independent Special Committee whose scope includes possible mergers and acquisitions of the Company."

"The Company continues to focus on closing near-term business development transactions to ensure that we have multiple options moving forward," stated J. Michael French, president and CEO of Marina Biotech. "As we explore all alternatives, it is imperative that we consider ourselves a potential acquisition target as our capabilities are complementary and synergistic with several other biotechnology companies."

The Company has retained Objective Capital Partners, LLC as its exclusive advisor to assist the Company in exploring such alternatives. The Company's independent Special Committee will oversee this process so that management can continue to execute the Company's ongoing initiatives and operations and bolster the position of its brand and business. The Company stated that there can be no assurance that the exploration of strategic alternatives will result in any transaction being entered into or consummated. The Company has not set a timetable for completion of this process unless or until the Board has approved a definitive course of action.

About Marina Biotech, Inc. Marina Biotech is an oligonucleotide therapeutics company with broad drug discovery technologies providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds, including messengerRNA therapeutics. These technologies were built via a roll-up strategy to discover and develop different types of nucleic acid therapeutics in order to modulate (up or down) a specific protein(s) which is either being produced too much or too little thereby causing a particular disease. We believe that the Marina Biotech technologies have unique strengths as a drug discovery engine for the development of nucleic acid-based therapeutics for rare and orphan diseases. Further, we believe Marina Biotech is the only company in the sector that has a delivery technology in human clinical trials with differentiated classes of payloads, through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively. Our novel chemistries and other delivery technologies have been validated through license agreements with Roche, Novartis, Monsanto, and Tekmira. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and a preclinical program in myotonic dystrophy. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at www.marinabio.com .

About Objective Capital Partners Objective Capital Partners ( www.objectivecp.com ) is a leading M&A investment banking firm whose Principals have collectively engaged in more than 500 successful transactions serving the transaction needs of growth stage and mid-size companies. The executive team has a unique combination of investment banking, private equity, and business ownership experience that enables Objective Capital Partners to provide large enterprise caliber investment banking services to companies with annual revenues up to $500 million. Services include sale transactions, equity and debt capital raises and comprehensive advisory services. The firm uses a proprietary process to work to achieve maximum company valuation, premium pricing, and high client satisfaction rates post-sale. The firm's industry expertise includes: life sciences, business services, software and hardware technology, aerospace/defense, IT services, healthcare services, energy services, biotech, consumer products and specialized manufacturing. Principals of Objective Capital Partners, are registered representatives of and Securities and Investment Banking Services are offered through BA Securities, LLC Member FINRA SIPC. Objective Capital Partners, LLC and BA Securities, LLC are separate and unaffiliated entities. Additional information on Objective Capital Partners is available at www.objectivecp.com .

Marina Biotech Forward-Looking Statements Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward looking statements are contained in Marina Biotech's most recent filings with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update or supplement forward-looking statements because of subsequent events.

For Marina acquisition and merger inquiries: Michael J. Kim Vice President(1) Objective Capital Partners, LLC Telephone: 858.264.6580 Email: Michael.Kim@objectivecp.com For Marina media, business and partnership inquires: J. Michael French President and CEO Marina Biotech, Inc. admin@marinabio.com (425) 892-4322 (1) Michael J. Kim is a registered representative of and Securities and Investment Banking Services are offered through BA Securities, LLC Member FINRA SIPC. Objective Capital Partners, LLC and BA Securities, LLC are separate and unaffiliated entities.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dimora's MegaSorb Review Sharpens Wound Care Choices

Updated Category News Views 105

Wound care is one of those corners of healthcare where flashy language runs into real-life consequences fast. Dimora Medical’s newly announced collaboration with podiatric physician Dr. Ebonie Vincent-Sleet brings a professional voice to its MegaSorb silicone foam dressing line, specifically a 4×4-inch product reviewed for its intended place in care. That is useful...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 80

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 174

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
Highway 99 Truck Death Puts Safety Records in Focus

Updated Category News Views 97

A stopped car on a highway shoulder is supposed to be a bad day, not a death sentence. Yet on November 5, 2026, a person helping a relative with a disabled vehicle was killed on northbound Highway 99 in Elk Grove after a commercial tractor-trailer allegedly drifted onto the shoulder, hit both stationary vehicles, and overturned. Northbound lanes were closed for hours. A...

Continue Reading
Cedar’s Fast 500 Spot Shows Billing Tech’s Momentum

Updated Category News Views 89

A 486th-place finish can look like the last seat on the bus, but Cedar’s 102% revenue growth from 2022 through 2025 is not nothing. Healthcare billing is a miserable, deeply entrenched corner of the economy where legacy systems have had decades to dig in. Growing at all while selling technology into health systems deserves a serious look, even if nobody should confuse a...

Continue Reading
A Quanzhou Table Offers China Beyond the Headlines

Updated Category News Views 7

Steam rising from a Quanzhou table can carry more weight than another polished speech about cultural exchange. That is the sensible instinct behind Home Banquets with Master Chefs, the CCTV-4 series using regional meals to explore geography, customs and memory. It is not trying to explain China through a pile of statistics or a museum-label summary. It starts where people...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 8

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 124

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Envision’s COP31 Pitch Hinges on Grid Execution, Not Targets

Updated Category News Views 24

A 2,500 GW traffic jam is a rotten place to park climate ambition. Envision Energy used COP31 in Antalya to make the more useful point: clean-power targets mean very little if grids cannot connect, balance and dispatch the electricity. Kane Xu’s message was not another round of flag-waving promises. It was an argument that the constraint has shifted from wanting...

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 131

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading

Top 5 Most Recently Viewed Articles

Edge Data Center Growth Driven by AI and Streaming Demand

Updated Category News Views 319

Edge Data Center Market Overview The edge data center market is projected to grow significantly, with an estimate of USD 22.11 billion growth from 2024 to 2028. This trend aligns with the increasing demand for video streaming services and the incorporation of artificial intelligence (AI) technologies into data center operations. With a compound annual growth rate (CAGR)...

Continue Reading
Four Attorneys Elevated to Director Roles at Goulston & Storrs

Updated Category News Views 209

Exciting Leadership Changes at Goulston & Storrs Goulston & Storrs, a distinguished Am Law 200 law firm based in Boston, is thrilled to announce the promotion of four exceptional attorneys to the role of Directors. This esteemed recognition reflects their dedication, expertise, and significant contributions to both the firm and its clients. Meet the New Directors Among...

Continue Reading
ODNB and NACB Merge: A Big Leap in Community Banking

Updated Category News Views 208

Merging Titans in Community Banking Folks, we've got a colossal merger happening in the cozy yet combative world of community banking—ODNB Financial Corporation is hitching wagons with National Capital Bancorp, Inc. Now, you'd be forgiven for not popping champagne over this unless your bread is buttered by $2.4 billion in assets and the shiny allure of becoming a big...

Continue Reading
Shell's Latest Prospectus Supplement Overview and Insights

Updated Category News Views 157

Shell International Finance B.V. and Shell plc Publish Prospectus Supplement Shell International Finance B.V. and Shell plc have recently made available significant financial documents for stakeholders and investors. This announcement revolves around the publication of their prospectus supplement. Available Financial Documents The following documents, hereafter referred...

Continue Reading
Jeff Lurie's Remarkable NFL Investment Journey and Success

Updated Category News Views 497

Jeff Lurie: From Professor to NFL Mogul Jeff Lurie, the proud owner of the Philadelphia Eagles, recently celebrated his second Super Bowl win, marking a significant milestone in a journey that began with a purchase of the franchise for $185 million back in 1994. Today, this team is valued at an astonishing 35 times that initial investment, showcasing Lurie’s sharp...

Continue Reading